Rafael Holdings Secures Exclusive MIT License for Cyclodextrin Therapy Targeting ApoE4-Positive Alzheimer's Patients
核心洞察
Rafael Holdings (搜索)' subsidiary Cyclo Therapeutics has entered into an exclusive licensing agreement with MIT covering U.S. Patent No.12285440 for cyclodextrin use in ApoE4 (搜索)-positive Alzheimer's disease (搜索) patients.
The ApoE4 (搜索) gene variant is present in 50-70% of Alzheimer's patients and is believed to be a key risk factor for early onset sporadic disease development.
Preclinical data suggest Trappsol® Cyclo™ can improve cholesterol delivery between CNS cells, reduce tau pathology, and enhance learning and memory in mice.
Rafael Holdings (搜索), Inc. (NYSE: RFL) announced that its subsidiary, Cyclo Therapeutics, has secured an exclusive licensing agreement with Massachusetts Institute of Technology covering U.S. Patent No.12285440. The license specifically covers the use of cyclodextrins in patients with Alzheimer's Disease (搜索) who carry an ApoE4 (搜索) genetic mutation, strengthening the company's intellectual property portfolio around Trappsol® Cyclo™ in this critical patient population.
Targeting a High-Risk Alzheimer's Population
The ApoE4 (搜索) gene variant is estimated to be present in 50-70% of patients with Alzheimer's disease (搜索) and is believed to be a key risk factor in the development of early onset sporadic AD. Dysregulated cholesterol metabolism is believed to contribute to amyloid and tau pathology, especially in those patients with the ApoE4 gene variant, which has been shown to accelerate AD as it is the key lipids/cholesterol transporter in the brain.
The established mechanism of action for Trappsol® Cyclo™ could have a direct impact in ApoE4 (搜索) positive patients as it has been shown to improve cholesterol transport between central nervous system (CNS) cells. Preclinical data suggest Trappsol® Cyclo™ can improve delivery of cholesterol between CNS cells, reduce tau-pathology and improve learning/memory in mice.
Strategic Significance and Leadership Perspective
"Securing this exclusive license from MIT represents a transformative milestone for our company and greater potential positive news for the millions of patients and their families affected by Alzheimer's disease (搜索)," said Howard Jonas, CEO, Executive Chairman and Chairman of the Board of Rafael Holdings (搜索). "By combining the results of MIT's world-class foundational research with our clinical development expertise, we are well positioned to accelerate a potential breakthrough that addresses the underlying pathology of this devastating condition. This agreement underscores our commitment to pursuing the highest caliber of innovation to deliver life-changing therapies to patients in need."
Broader Pipeline Development
The licensing agreement comes as Rafael Holdings (搜索) advances its lead candidate across multiple indications. "With Phase 3 results from Transport NPC due in calendar Q3, 2026, we're excited by Trappsol® Cyclo™'s potential across multiple disease areas," said Joshua Fine, COO of Rafael Holdings. "Our NPC1 phase 3 study is the largest ever conducted in patients with NPC, yielding crucial clinical and safety data needed to advance the treatment paradigm for patients and families dealing with NPC."
Rafael Holdings (搜索) is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. The company's lead candidate, Trappsol® Cyclo™, is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (搜索) (NPC1), a rare, fatal and progressive genetic disorder, and is the subject of an ongoing pivotal Phase 3 clinical trial.